Thailand sets mid-October to reopen to vaccinated visitors

Wednesday, June 16, 2021 | Chalida Ekvittayavechnukul, Associated Press

Prayuth Chan-ocha
In this Feb. 24, 2021, file photo, Prime Minister Prayuth Chan-ocha holds samples of the Sinovac vaccine during a ceremony to mark the arrival of 200,000 doses in a shipment at the Suvarnabhumi airport in Bangkok. Prayuth on Wednesday, June 16, 2021, declared that the country is planning to fully reopen to foreign visitors without restrictions by mid-October, as the government seeks to restart the crucial tourist industry, heavily hit by the coronavirus pandemic. (AP Photo/Sakchai Lalit, File)

BANGKOK (AP) — Thailand plans to fully reopen to vaccinated foreign visitors by mid-October as the government seeks to restart the crucial coronavirus-devastated tourism industry, the prime minister announced Wednesday.

Prime Minister Prayuth Chan-ocha said fully inoculated foreign visitors and returning Thai citizens must be allowed entry “without quarantine or other inconvenient restrictions,” and that his goal is to open up the country within 120 days.

Prayuth acknowledged that the push to re-open might create problems.

“I know this decision comes with some risk because, when we open the country, there will be an increase in infections, no matter how good our precautions,” he said. “But I think when we take into consideration the economic needs of the people, the time has come for us to take that calculated risk.”

Tourism is a major contributor to Thailand's economy and employs millions of people. The country attracted nearly 40 million foreign arrivals in 2019, which plunged in 2020 because of an entry ban to control the coronavirus.

Prayuth said the government would reconsider the reopening only if a serious situation develops.

The government had previously targeted next January for reopening the country.

Thailand is in the midst of a surge in coronavirus cases that started in April and has accounted for more than 80% of the country’s 204,595 total confirmed cases and 90% of its 1,525 deaths.

The surge has caused special concern because Thailand has been late in securing and deploying vaccine supplies. So far it only has supplies of Sinovac from China and AstraZeneca, which is beginning to be produced locally under license. Just over 7% of the country's 69 million people have had at least one dose.

Prayuth, who has come under fierce criticism over the vaccine supply situation, said his government is making progress in obtaining other vaccines, including those from Pfizer, Johnson & Johnson and Moderna.

“To date, we have signed reservation and supply contracts for 105.5 million doses to be delivered this year, putting us ahead of our target for vaccine supplies,” he said. “Based on our current plans, we will administer an average of about 10 million shots a month from July, so that by early October almost 50 million people will have had at least their first shot administered."

Thailand plans to begin a trial project next month in which it will allow fully vaccinated visitors from abroad to enter Phuket without quarantine. But the so-called “Phuket sandbox” still entails restrictions, including a requirement to stay on the island for 14 days before heading to the mainland.

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)2.4$174.49+0.1%2.43%26.24Buy$190.38
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.